Literature DB >> 29860199

Validating the portal population of the United Kingdom Multiple Sclerosis Register.

R M Middleton1, W J Rodgers2, J Chataway3, K Schmierer4, D Rog5, I Galea6, A Akbari2, K Tuite-Dalton2, H Lockhart-Jones2, D Griffiths2, D G Noble2, K H Jones2, A Al-Din7, M Craner8, N Evangelou9, P Harman10, T Harrower11, J Hobart12, H Husseyin13, M Kasti14, C Kipps15, G McDonnell16, C Owen17, O Pearson18, W Rashid19, H Wilson20, D V Ford2.   

Abstract

The UK Multiple Sclerosis Register (UKMSR) is a large cohort study designed to capture 'real world' information about living with multiple sclerosis (MS) in the UK from diverse sources. The primary source of data is directly from people with Multiple Sclerosis (pwMS) captured by longitudinal questionnaires via an internet portal. This population's diagnosis of MS is self-reported and therefore unverified. The second data source is clinical data which is captured from MS Specialist Treatment centres across the UK. This includes a clinically confirmed diagnosis of MS (by Macdonald criteria) for consented patients. A proportion of the internet population have also been consented at their hospital making comparisons possible. This dataset is called the 'linked dataset'. The purpose of this paper is to examine the characteristics of the three datasets: the self-reported portal data, clinical data and linked data, in order to assess the validity of the self-reported portal data. The internet (n = 11,021) and clinical (n = 3,003) populations were studied for key shared characteristics. We found them to be closely matched for mean age at diagnosis (clinical = 37.39, portal = 39.28) and gender ratio (female %, portal = 73.1, clinical = 75.2). The Two Sample Kolmogorov-Smirnov test was for the continuous variables to examine is they were drawn from the same distribution. The null hypothesis was rejected only for age at diagnosis (D = 0.078, p < 0.01). The populations therefore, were drawn from different distributions, as there are more patients with relapsing disease in the clinical cohort. In all other analyses performed, the populations were shown to be drawn from the same distribution. Our analysis has shown that the UKMSR portal population is highly analogous to the entirely clinical (validated) population. This supports the validity of the self-reported diagnosis and therefore that the portal population can be utilised as a viable and valid cohort of people with Multiple Sclerosis for study.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Data linkage; Longitudinal; Multiple sclerosis; PROMs; Research register; Validation

Mesh:

Year:  2018        PMID: 29860199     DOI: 10.1016/j.msard.2018.05.015

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  8 in total

1.  Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland.

Authors:  Marco Kaufmann; Jens Kuhle; Milo A Puhan; Christian P Kamm; Andrew Chan; Anke Salmen; Jürg Kesselring; Pasquale Calabrese; Claudio Gobbi; Caroline Pot; Nina Steinemann; Stephanie Rodgers; Viktor von Wyl
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-12-06

2.  Regional variation in the incidence rate and sex ratio of multiple sclerosis in Scotland 2010-2017: findings from the Scottish Multiple Sclerosis Register.

Authors:  Patrick K A Kearns; Martin Paton; Martin O'Neill; Chrissie Waters; Shuna Colville; James McDonald; Ian J B Young; Dan Pugh; Jonathon O'Riordan; Belinda Weller; Niall MacDougall; Tom Clemens; Chris Dibben; James F Wilson; Marcia C Castro; Alberto Ascherio; Siddharthan Chandran; Peter Connick
Journal:  J Neurol       Date:  2019-06-11       Impact factor: 4.849

3.  Personal and societal costs of multiple sclerosis in the UK: A population-based MS Registry study.

Authors:  Richard S Nicholas; Martin L Heaven; Rodden M Middleton; Manoj Chevli; Ruth Pulikottil-Jacob; Kerina H Jones; David V Ford
Journal:  Mult Scler J Exp Transl Clin       Date:  2020-01-22

4.  Remote testing of vitamin D levels across the UK MS population-A case control study.

Authors:  Nicola Vickaryous; Mark Jitlal; Benjamin Meir Jacobs; Rod Middleton; Siddharthan Chandran; Niall John James MacDougall; Gavin Giovannoni; Ruth Dobson
Journal:  PLoS One       Date:  2020-12-30       Impact factor: 3.240

5.  Creating a Digital Toolkit to Reduce Fatigue and Promote Quality of Life in Multiple Sclerosis: Participatory Design and Usability Study.

Authors:  Sarah Thomas; Andy Pulman; Huseyin Dogan; Nan Jiang; David Passmore; Keith Pretty; Beth Fairbanks; Angela Davies Smith; Peter W Thomas
Journal:  JMIR Form Res       Date:  2021-12-09

6.  Defining routine fatigue care in Multiple Sclerosis in the United Kingdom: What treatments are offered and who gets them?

Authors:  Federica Picariello; Jennifer Freeman; Rona Moss-Morris
Journal:  Mult Scler J Exp Transl Clin       Date:  2022-01-20

7.  The impact of smoking cessation on multiple sclerosis disease progression.

Authors:  Jeff Rodgers; Tim Friede; Frederick W Vonberg; Cris S Constantinescu; Alasdair Coles; Jeremy Chataway; Martin Duddy; Hedley Emsley; Helen Ford; Leonora Fisniku; Ian Galea; Timothy Harrower; Jeremy Hobart; Huseyin Huseyin; Christopher M Kipps; Monica Marta; Gavin V McDonnell; Brendan McLean; Owen R Pearson; David Rog; Klaus Schmierer; Basil Sharrack; Agne Straukiene; Heather C Wilson; David V Ford; Rod M Middleton; Richard Nicholas
Journal:  Brain       Date:  2022-05-24       Impact factor: 15.255

8.  A Rapid Electronic Cognitive Assessment Measure for Multiple Sclerosis: Validation of Cognitive Reaction, an Electronic Version of the Symbol Digit Modalities Test.

Authors:  Rod M Middleton; Owen R Pearson; Gillian Ingram; Elaine M Craig; William J Rodgers; Hannah Downing-Wood; Joseph Hill; Katherine Tuite-Dalton; Christopher Roberts; Lynne Watson; David V Ford; Richard Nicholas
Journal:  J Med Internet Res       Date:  2020-09-23       Impact factor: 5.428

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.